Laurence Lapauw

Laurence Lapauw

Auto-generated profile, based on publicly available information

Laurence Lapauw

Department of Public Health and Primary Care, Division of Gerontology and Geriatrics, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Experimental Gerontology
Verified
Journal Article
Open access
JDJolan Dupont
Jolan Dupont
LVLaura Vercauteren
Laura Vercauteren
NANadjia Amini
Nadjia Amini
LLLaurence Lapauw
Laurence Lapauw
MSMaxim De Schaepdryver
Maxim De Schaepdryver
EGEvelien Gielen
Evelien Gielen
To explore the relationship between inflammatory markers and sarcopenia-related traits in sarcopenic older adults. Baseline data of the ongoing Exercise and Nutrition for Healthy AgeiNg (ENHANce) study were used for a secondary, exploratory, cross-sectional analysis. ENHANce is a 5-armed triple blinded randomized controlled trial, in older adults (>65y) with sarcopenia defined according to the revised criteria of the European Working Group of Sarcopenia in Older People (EWGSOP2) aiming to assess the effect of combined anabolic interventions (protein supplement, omega-3 supplement and physical exercise) on physical performance, compared to single/placebo interventions. Inflammatory markers C-reactive protein (hs-CRP), albumin, interleukin-1β (IL-1β), IL-6, IL-8, and tumour necrosis factor-α (TNF-α) were assessed at baseline. Spearman's rho (ρ) correlation coefficients were calculated to associate these inflammatory markers with baseline sarcopenia-defining parameters (handgrip strength, chair stand test, appendicular lean mass [aLM], gait speed, Short Physical Performance Battery), physical activity (step count) and quality of life (SF-36, SarQoL). We included 40 sarcopenic subjects (15 men/25 women, age 77.1 ± 6.8 years). Contrary to expectations, the pro-inflammatory IL-1β correlated positively with handgrip strength (ρ: 0.376; p = 0.024) and IL-6 with aLM (ρ: 0.334; p = 0.0433). IL-6 inversely correlated with step count (ρ:-0.358; p = 0.048). Subgroup analysis revealed important gender differences. IL-8 inversely correlated with handgrip strength in women (ρ: -0.425; p = 0.034) but not in men. In contrast, pro-inflammatory cytokines CRP (ρ: -0.615; p = 0.019), IL-6 (ρ: -0.604; p = 0.029) and TNF-α (ρ: -0.615; p = 0.025) inversely correlated with the SF-36 physical component score in men but not in women. Although Inflammageing might play a role in sarcopenia-related traits, this exploratory study highlights an important role of gender. Future research should take this into account when elucidating the Inflammageing-sarcopenia interplay.

27 August 2024 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
LLLaurence Lapauw
Laurence Lapauw
ARAurélie Rutten
Aurélie Rutten
JDJolan Dupont
Jolan Dupont
NANadjia Amini
Nadjia Amini
LVLaura Vercauteren
Laura Vercauteren
EGEvelien Gielen
Evelien Gielen
Altered gut microbiota (GM) potentially contribute to development or worsening of sarcopenia through a gut‐muscle axis. This systematic review aims to compare GM between persons with sarcopenia or low sarcopenia‐defining parameters (muscle mass, strength, and physical performance) to those with preserved muscle status, as well as to clarify possible associations between sarcopenia (‐defining parameters) and relative abundance (RA) of GM‐taxa or GM‐(α‐ or β) diversity indices, in order to clarify whether there is robust evidence of the existence of a GM signature for sarcopenia. This systematic review was conducted according to the PRISMA‐reporting guideline and pre‐registered on PROSPERO (CRD42021259597). PubMed, Web of Science, Embase, ClinicalTrials.gov, and Cochrane library were searched until 20 July 2023. Included studies reported on GM and sarcopenia or its defining parameters. Observational studies were included with populations of mean age ≥50 years. Thirty‐two studies totalling 10 781 persons (58.56% ♀) were included. Thirteen studies defined sarcopenia as a construct. Nineteen studies reported at least one sarcopenia‐defining parameter (muscle mass, strength or physical performance). Studies found different GM‐taxa at multiple levels to be significantly associated with sarcopenia (n = 4/6), muscle mass (n = 13/14), strength (n = 7/9), and physical performance (n = 3/3); however, directions of associations were heterogeneous and also conflicting for specific GM‐taxa. Regarding β‐diversity, studies found GM of persons with sarcopenia, low muscle mass, or low strength to cluster differently compared with persons with preserved muscle status. α‐diversity was low in persons with sarcopenia or low muscle mass as compared with those with preserved muscle status, indicating low richness and diversity. In line with this, α‐diversity was significantly and positively associated with muscle mass (n = 3/4) and muscle strength (n = 2/3). All reported results were significant (P < 0.05). Persons with sarcopenia and low muscle parameters have less rich and diverse GM and can be separated from persons with preserved muscle mass and function based on GM‐composition. Sarcopenia and low muscle parameters are also associated with different GM‐taxa at multiple levels, but results were heterogeneous and no causal conclusions could be made due to the cross‐sectional design of the studies. This emphasizes the need for uniformly designed cross‐sectional and longitudinal trials with appropriate GM confounder control in large samples of persons with sarcopenia and clearly defined core outcome sets in order to further explore changes in GM‐taxa and to determine a sarcopenia‐specific GM‐signature.

5 May 2023 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
JDJolan Dupont
Jolan Dupont
EWEva Wauters
Eva Wauters
LDLenore Dedeyne
Lenore Dedeyne
LVLaura Vercauteren
Laura Vercauteren
NANadjia Amini
Nadjia Amini
EGEvelien Gielen
Evelien Gielen
Aims: To explore the relationship between dietary polyunsaturated fatty acids (PUFAs) intake, nutritional PUFAs status and sarcopenia outcomes in sarcopenic older adults. Methods: The Exercise and Nutrition for Healthy AgeiNg (ENHANce) is an ongoing 5-armed triple blinded randomized controlled trial, in sarcopenic older adults (> 65y) aiming to assess the effect of combined anabolic interventions (protein, omega-3 supplement and exercise) on physical performance in these adults, compared to single/placebo interventions. Baseline data were used for a secondary, exploratory, cross-sectional analysis. Dietary PUFAs intake was assessed with 4-day food records, status with RBC membrane fatty acids profiles. Spearman’s rho(ρ) correlation coefficients were calculated to explore associations of PUFAs intake and status with sarcopenia-defining parameters (muscle strength, mass and physical performance), physical activity (step count) and quality of life (SF-36, SarQoL). Results: In total, 29 subjects (9♂/20♀, mean age 76.3 ± 5.4y) were included. Total omega-3 intake of participants (1.99 ± 0.99 g/d) was below the recommended intake (♂:2.8–5.6 g/d; ♀:2.2–4.4 g/d). Intake and status of PUFAs were not correlated. Regarding correlations with outcomes, α-linolenic acid status was inversely associated with appendicular lean mass (aLM) (ρ:-0.439; p = 0.017), whereas docosahexaenoic acid status was positively associated with aLM (ρ:0.388; p = 0.038). Some omega-3 PUFAs intake and status markers were positively associated with step count, SF-36 and SarQoL scores, whereas gamma-linolenic acid status was inversely associated with SF-36 physical component summary score (ρ = -0.426; p = 0.024). Conclusions: Although intake of omega-3 and omega-6 was low, the present exploratory study generated new hypotheses for potential correlations of PUFAs intake and status with sarcopenia outcomes in older adults with sarcopenia.

6 September 2024 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
MSMeng Shang
Meng Shang
LDLenore Dedeyne
Lenore Dedeyne
JDJolan Dupont
Jolan Dupont
LVLaura Vercauteren
Laura Vercauteren
NANadjia Amini
Nadjia Amini
Bart VanrumsteBart Vanrumste
Bart Vanrumste
The Otago Exercise Program (OEP) represents a crucial rehabilitation initiative tailored for older adults, aimed at enhancing balance and strength. Despite previous efforts utilizing wearable sensors for OEP recognition, existing studies have exhibited limitations in terms of accuracy and robustness. This study addresses these limitations by employing a single waist-mounted Inertial Measurement Unit (IMU) to recognize OEP exercises among community-dwelling older adults in their daily lives. A cohort of 36 older adults participated in laboratory settings, supplemented by an additional 7 older adults recruited for at-home assessments. The study proposes a Dual-Scale Multi-Stage Temporal Convolutional Network (DS-MS-TCN) designed for two-level sequence-to-sequence classification, incorporating them in one loss function. In the first stage, the model focuses on recognizing each repetition of the exercises (micro labels). Subsequent stages extend the recognition to encompass the complete range of exercises (macro labels). The DS-MS-TCN model surpasses existing state-of-the-art deep learning models, achieving f1-scores exceeding 80% and Intersection over Union (IoU) f1-scores surpassing 60% for all four exercises evaluated. Notably, the model outperforms the prior study utilizing the sliding window technique, eliminating the need for post-processing stages and window size tuning. To our knowledge, we are the first to present a novel perspective on enhancing Human Activity Recognition (HAR) systems through the recognition of each repetition of activities.

26 September 2023 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
LLLaurence Lapauw
Laurence Lapauw
JDJolan Dupont
Jolan Dupont
NANadjia Amini
Nadjia Amini
LVLaura Vercauteren
Laura Vercauteren
SVSabine Verschueren
Sabine Verschueren
EGEvelien Gielen
Evelien Gielen
Background: Gut microbiota (GM) might play a role in muscle metabolism and physiological processes through a hypothesized gut-muscle axis, influencing muscle mass and function and thus, sarcopenia. The Trial in Elderly with Musculoskeletal Problems due to Underlying Sarcopenia—Faeces to Unravel the Gut and Inflammation Translationally (TEMPUS-FUGIT) aims to explore the gut-muscle axis in sarcopenia. Methods: First, in a cross-sectional case–control phase, 100 community-dwelling adults without sarcopenia will be compared to 100 community-dwelling adults (≥ 65 years) with sarcopenia of similar age-, gender and BMI-ratio, participating in the ongoing ‘Exercise and Nutrition for Healthy AgeiNg’ (ENHANce; NCT03649698) study. Sarcopenia is diagnosed according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. GM composition and intestinal inflammatory markers (fecal calprotectin, lactoferrin and S100A12) will be determined in fecal samples. Systemic inflammatory markers (hs-CRP, IL-4, IL-6, TNF-α, IL-13, IL-1β and creatine kinase) will be determined in fasted blood samples. Both groups will be compared using appropriate statistical testing, whereas linear regression will be used for cross-sectional associations between gut, inflammatory and sarcopenia parameters. Second, in the longitudinal phase, sarcopenic older adults will be requested to deliver five fecal samples during the 12-week intervention to assess the effects of protein, omega-3 and a physical exercise program on the GM. Discussion: TEMPUS-FUGIT aims to explore the gut-muscle axis by comparing GM composition between sarcopenic and non-sarcopenic older adults and to determine the association of GM with intestinal and systemic inflammatory markers and sarcopenia-defining parameters (muscle mass, muscle strength and physical performance). Furthermore, effects of single or combined, optimized and individualized anabolic interventions (exercise, protein and omega-3 supplementation), on GM will be explored in persons with sarcopenia. TEMPUS-FUGIT aims to impact clinical practice by clarifying the relationship between the gut-muscle axis and sarcopenia. TEMPUS-FUGIT is expected to contribute to the discovery of clinical and microbial biomarkers for sarcopenia and insights in its pathophysiology, opening possible future perspectives for novel sarcopenia treatment strategies targeting GM. Trial registration: ClinicalTrails.gov NCT05008770, registered on August 17, 2021; first participant enrolled on September 21 2021.

21 November 2025 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
LLLaurence Lapauw
Laurence Lapauw
NANadjia Amini
Nadjia Amini
ESEmiel Switsers
Emiel Switsers
JDJolan Dupont
Jolan Dupont
LVLaura Vercauteren
Laura Vercauteren
EGEvelien Gielen
Evelien Gielen
Aim To investigate effects of host- and gut microbiota (GM)-altering interventions on sarcopenia (parameters). Methods Upon PROSPERO registration (CRD42022347363), six databases and one registry were searched until January 5th 2024 and updated on June 10th 2025 for diet, pre-, pro-, or synbiotics mono-interventions in populations with mean age ≥ 50 years. (Standardized) mean differences (SMD) and 95% confidence intervals (CI) were computed using random-effects models if heterogeneity was > 50%. Risk of bias (Rob) & GRADE assessments were carried out to assess the evidence’ quality and certainty. Results The qualitative analysis included 38 diet, 13 prebiotics, 11 probiotics and 1 synbiotics studies, totaling 4842 participants (59%♀), mostly of high RoB. The quantitative analysis included 49 studies. Probiotics improved muscle strength by 1.90 kg and gait speed by 0.08 m/s. Fiber (whole-food)-enriched diets improved muscle strength with 1.25 kg and energy-restricted diets, aimed at weight loss, improved muscle mass if mean age was < 60 years and if the intervention lasted no longer than 12 weeks. High-protein diets improved muscle mass in women and if the intervention lasted at least 12 weeks. Studies involving participants with sarcopenia were only included in the qualitative analysis, since none provided sufficient data to allow a quantitative synthesis. Discussion Fiber (whole food)-enriched diets and probiotics improve muscle strength. The latter intervention also improves gait speed. High-protein diets improve muscle mass in women and with intervention durations ≥ 12 weeks. Future studies should include fecal sampling to assess whether GM modulate the observed effects. Conclusion Specific diets and probiotics offer potential to improve sarcopenia parameters.